Kawata et al. [75] designed a novel nanosized delivery system of tissue-type plasminogen activator (t-PA) as a therapy to coronary thrombolysis; the results showed it had a suppressed thrombolytic activity of t-PA in acute myocardial infarction model after injecting of t-PA nanoparticles (25% t-PA, 55000 iu/kg) and would not increase the risk of bleeding but recovered the activity only under the action of ultrasound (1.0 MHz, 1.0 W/cm2) (Figure 7). This evidence concerns the gene PLAT and acute myocardial infarction.